Pros and cons of different therapeutic antibody formats for recombinant antivenom development.
Laustsen AH, María Gutiérrez J, Knudsen C, Johansen KH, Bermúdez-Méndez E, Cerni FA, Jürgensen JA, Ledsgaard L, Martos-Esteban A, Øhlenschlæger M, Pus U, Andersen MR, Lomonte B, Engmark M, Pucca MB.
Laustsen AH, et al.
Toxicon. 2018 May;146:151-175. doi: 10.1016/j.toxicon.2018.03.004. Epub 2018 Mar 10.
Toxicon. 2018.
PMID: 29534892
Free article.
Review.